130 related articles for article (PubMed ID: 16086096)
1. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Amato RJ; Rawat A
Invest New Drugs; 2006 May; 24(3):171-5. PubMed ID: 16086096
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
3. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Amato RJ; Mohammad T
J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
6. [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Shi SB; Ma TH; Tang XY; Li CH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):301-4. PubMed ID: 23985261
[TBL] [Abstract][Full Text] [Related]
7. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Kraemer A; Hauser S; Kim Y; Gorschlüter M; Müller SC; Brossart P; Schmidt-Wolf IG
Ger Med Sci; 2009 Jun; 7():Doc04. PubMed ID: 19675744
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide therapy for renal cell carcinoma.
Amato RJ
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S59-65. PubMed ID: 12850528
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Laber DA; Khan MI; Kloecker GH; Schonard C; Taft BS; Salvador C
Cancer Biol Ther; 2007 Jun; 6(6):840-5. PubMed ID: 17582215
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
17. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
[TBL] [Abstract][Full Text] [Related]
18. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
20. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
